Prominent pharmaceutical companies in Europe, including AstraZeneca and GSK, have issued a stark warning regarding the future of the pharmaceutical industry as Europe faces intensified competition from the United States and China in medical research. In an open letter, these industry leaders, together with counterparts from Novo Nordisk, Sanofi, Roche, and Novartis, expressed concern that the continent is losing its competitive edge in the global landscape of pharmaceuticals.

The letter cautioned that without immediate and decisive action, strategic sectors like pharmaceuticals could undergo a prolonged decline. The pharmaceutical sector, deemed one of Europe’s significant post-war successes, is at risk, necessitating European governments to foster conditions that would attract investment in next-generation medicines promptly.

A notable decline in Europe’s global standing in pharmaceutical research and development was highlighted, with Europe’s share dropping from 43% in 1990 to 31% in recent years. During this same period, China has surged ahead, outperforming Europe in critical areas such as clinical trials, pharmaceutical patents, and the development of new medicines. Furthermore, the letter pointed out alarming delays in the launch of newly approved treatments within Europe, reinforcing the disheartening message to innovators: Europe does not adequately appreciate their contributions.

The dynamics within the pharmaceutical industry are muddled by ongoing disputes regarding the adequacy of incentives provided by European governments for life-sciences investments. In the UK, significant friction arose last year when industry leaders confronted then-Health Secretary Wes Streeting over the rebate obligations imposed on drug sales to the NHS. Those rates ultimately saw reductions following pressure from former US President Donald Trump, who accused Europe of taking advantage of American advancements in the drug sector, influencing costs incurred by UK taxpayers.

The commitment of AstraZeneca to invest $50 billion in the US has further heightened concerns about the company's future presence on the London Stock Exchange. China's evolution from a market known for affordable, imitation drugs to a robust player in the pharmaceutical landscape is underscored by its ability to conduct clinical trials more efficiently and at a considerably lower cost compared to Europe.

The pharmaceutical executives further revealed that up to 40% of newly approved therapies fail to reach European patients, adding that, for those that do, patients may endure delays lasting nearly 600 days before treatment becomes available. According to the letter, the potential loss of Europe's €220 billion trade surplus in pharmaceuticals is imminent. The executives estimated that resolving the discrepancies in clinical trials could yield up to €53 billion in additional economic value and generate approximately 82,000 jobs.

The letter's signatories asserted that unless Europe takes ambitious steps, the region's role in pharmaceuticals will continue to decline, jeopardising its ability to foster innovation. They posited that prioritising investment in health and medicine as strategic resources could enable Europe not only to catch up with global competitors but also to reclaim a leadership position in setting the pace for worldwide innovation, ultimately contributing to longer and healthier lives for its residents.

In response, a Government spokesperson noted the Life Sciences Sector Plan, aiming to position the UK among the top three life science powers globally by 2035, has already secured upwards of £3 billion in private investment since last July. The spokesperson added that ongoing investments from firms including AstraZeneca and Moderna are pivotal in supporting British research and development, fostering economic growth and opportunities throughout the country. The government emphasised its commitment to creating a stable environment for companies, encouraging them to invest confidently and develop future medicines in the UK.